REGINfo: MSI - Financial information

SEARCH BY

Issuer directory

KEYWORDS

COMPANIES / ISIN

TYPE OF INFORMATION

INDUSTRY

ADVANCED SEARCH

COMPARTMENTS / INDICES

France

America

Asia

Oceania

> ASX 20
Australia - ASX 20
> NZX 15
New Zealand - NZX 15

Africa

> FTSE/JSE...
South Africa - FTSE/JSE Top 40
- Remgro
- RICHEMONT
- RMB Holdings
- Sanlam
- Sasol
- Shoprite
- Standard Bank Group
- Tiger Brands
- Vodacom Group
- WOOLWORTHS
> TA 25
Israel - TA 25
- AVNER OIL
- AZRIELI GROUP
- BEZEQ
- DELEK DRILLIN
- DISCOUNT
- ELBIT SYSTEMS
- FIBI BANK
- GAZIT GLOBE
- ICL
- IFF
- ISRAEL CORP
- KENON
- LEUMI
- MIGDAL INSURANCE
- MIZRAHI TEFAHOT
- NICE
- OPKO HEALTH
- OSEM
- PAZ OIL
- PERRIGO
- POALIM
- STRAUSS GROUP
- TEVA

Europe

INDEX SEARCH RESULT

2019.11.18 | 07:00 | Permanent Information Releases / General Company News

ROCHE

puce Roche to present new and updated data for seven approved and investigational medicines across multiple types of breast cancer at the 2019 San Antonio Breast Cancer Symposium - HTML (w)

2019.11.17 | 16:45 | Permanent Information Releases / General Company News

NOVARTIS

puce Novartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF - HTML (w)

2019.11.15 | 21:06 | Permanent Information Releases / General Company News

NOVARTIS

puce New Novartis medicine Adakveo® (crizanlizumab) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease - HTML (w)

2019.11.15 | 13:18 | Permanent Information Releases / General Company News

ROCHE

puce CHMP recommends EU approval of Roche’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment - HTML (w)

2019.11.15 | 13:15 | Permanent Information Releases / General Company News

ROCHE

puce CHMP recommends conditional EU approval of Roche’s Polivy for people with previously treated aggressive lymphoma - HTML (w)

2019.11.15 | 12:27 | Permanent Information Releases / General Company News

NOVARTIS

puce Novartis receives positive CHMP opinion for Mayzent® (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS) - HTML (w)

2019.11.14 | 18:12 | Annual General Meeting / Reports

ARYZTA AG

puce ARYZTA AG AGM Result - HTML (w)

2019.11.14 | 07:00 | Permanent Information Releases / General Company News

SIKA

puce SIKA ERÖFFNET MÖRTELFABRIK IN ÄTHIOPIEN - HTML (w)

2019.11.14 | 07:00 | Permanent Information Releases / General Company News

SIKA

puce SIKA OPENS MORTAR PLANT IN ETHIOPIA - HTML (w)

2019.11.12 | 07:25 | Permanent Information Releases / General Company News

NOVARTIS

puce Sandoz presents real-world data showing effectiveness of Erelzi® (etanercept-szzs) in rheumatic disease treatment - HTML (w)

2019.11.12 | 07:15 | Permanent Information Releases / General Company News

NOVARTIS

puce New Novartis PREVENT data show Cosentyx® delivers early relief in axial spondyloarthritis - HTML (w)

2019.11.11 | 07:03 | Permanent Information Releases / General Company News

ROCHE

puce Roche’s Gazyva (obinutuzumab), in combination with standard of care, more than doubles the percentage of lupus nephritis patients achieving complete renal response, compared to standard of care alone - HTML (w)

2019.11.11 | 07:00 | Permanent Information Releases / General Company News

ROCHE

puce Roche’s risdiplam meets primary endpoint in pivotal SUNFISH trial in people with type 2 or 3 spinal muscular atrophy - HTML (w)

2019.11.11 | 07:00 | Permanent Information Releases / General Company News

NOVARTIS

puce Sandoz announces agreement to acquire Aspen’s Japanese operations and associated assets, strengthening position in world’s third largest generics market - HTML (w)

2019.11.06 | 17:35 | Permanent Information Releases / General Company News

ROCHE

puce Roche to present new data highlighting breadth of haematology portfolio and pipeline at the American Society of Hematology 2019 Annual Meeting - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 1000